Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: focus on dosing regimen, dosage form, and formulation.
Chen
Mei-Ling
ML
Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA. chenme@cder.fda.gov
D002626:Chemistry, Pharmaceutical; D015986:Confounding Factors, Epidemiologic; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D004304:Dosage Forms; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000378:metabolism*; D010599:Pharmacokinetics; D010600:Pharmacology; D012737:Sex Factors
D004304:Dosage Forms; D004364:Pharmaceutical Preparations; D003577:Cytochrome P-450 Enzyme System; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A